Lantern Pharma LTRN 深 滬
已收盤 09-05 16:00:00 美东时间
4.31
+0.110
+2.62%
華盛通- 最 高4.38
- 今 開4.19
- 成交量 6.07万股
- 最 低 4.14
- 昨 收 4.20
- 總市值 4648.21万
- 52周最高 6.118
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 2.55
- 委 比 39.07%
- 總股本 1078.47万
- 歷史最高 24.84
- 量 比 0.72
- 振 幅 5.71%
- 歷史最低 2.38
- 每 手 1
- 風險率 1.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform,
09-03 21:47
Lantern Pharma shares are trading lower. The company reported Q2 financial results.
Lantern Pharma shares are trading lower. The company reported Q2 financial resu...
08-14 23:52
Lantern Pharma Q2 EPS $(0.40) Beats $(0.48) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 17.53 percent. This is a 13.04 percent increase over losses of $(0.46) per share from
08-14 04:36
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
Lantern Pharma Completes Early Enrollment in Japan for Lung Cancer Trial Targeting Never-Smokers
Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the successful completion of targeted
07-31 19:35
Lantern Pharma Appoints Dr. Schalop to Board
Lantern Pharma ( ($LTRN) ) has shared an announcement. Lantern Pharma Inc. anno...
07-30 05:29
Lantern Pharma Reports Complete Metabolic Response In A Heavily Pre-Treated Lymphoma Patient With LP-284 In Its Phase 1 Clinical Trial
AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens.Complete response in an aggressive, recurring B-cell
07-23 19:58
Lantern Pharma Secures FDA Approval For Phase 1B/2 Clinical Trial For LP-184 + Olaparib In Triple-Negative Breast Cancer
The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair
07-15 21:42
Lantern Pharma Enters $15.53M At-The-Market Offering Agreement With ThinkEquity
On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the "Sales Agreement") with ThinkEquity LLC (the "Agent"), pursuant to which the Company may offer and
07-04 04:14
Lantern Pharma Announces Preclinical Data For LP-184 In Atypical Teratoid Rhabdoid Tumors, Rare And Aggressive Pediatric Brain Cancer
Independent research from Johns Hopkins validates Lantern's data used to secure the FDA Rare Pediatric Disease Designation for LP-184 in ATRT and supports planned pediatric clinical trialLantern Pharma Inc.
05-29 20:32
